|

BAY2927088 Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: Sevabertinib

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Bayer2

Indications

  • HER2 Mutation2
  • Cancer2
  • Advanced Non-Small Cell Lung Cancer1
  • Advanced Solid Tumors1
  • Lung Cancer1

Birmingham, Alabama1 trial

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital

Phase 2

Newport Beach, California1 trial

A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Patty & George Hoag Cancer Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.